DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02273960 (ClinicalTrials.gov)	November 17, 2014	3/10/2014	Study to Evaluate Safety and Efficacy in Adult Subjects With ITP	Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)	Immune Thrombocytopenic Purpura	Drug: BMS-986004 75 mg IV;Drug: BMS-986004 225 mg IV;Drug: BMS-986004 675 mg IV;Drug: BMS-986004 1500 mg IV	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	46	Phase 1;Phase 2	United States;Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02273960
(ClinicalTrials.gov)

November 17, 2014

3/10/2014

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic Purpura

Drug: BMS-986004 75 mg IV;Drug: BMS-986004 225 mg IV;Drug: BMS-986004 675 mg IV;Drug: BMS-986004 1500 mg IV

Bristol-Myers Squibb

NULL

Completed

18 Years

N/A

All

Phase 1;Phase 2

United States;Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom